论文部分内容阅读
阿耳茨海默氏病(AD,早老性痴呆)是一种病因不明的记忆和智力功能逐渐减退的脑功能障碍症。此病随着年龄的增长而发病率增高。由于涉及老龄人的公共健康问题,而且预期今后数十年老龄人数将显著增加,几种改善AD症状的治疗法相继在临床试验中。据观察,AD病患者特别缺乏胆碱乙酰化酶(CAT)。CAT是乙酰胆碱的生物合成酶和突触前神经元的标记。此外,还观察到AD患者的布罗卡核基系统中的septal-diagonal band上选择性地失去了胆碱能神经元。这些神经化学和组织学的变化与AD的关系对
Alzheimer’s disease (AD, Alzheimer’s disease) is an impaired memory and impaired intellectual function of brain dysfunction. The disease increases with age and increased incidence. Due to the public health concerns of older persons, and the expected aging population will increase significantly in the coming decades, several treatments to improve the symptoms of AD have been in clinical trials one after another. It is observed that patients with AD are particularly deficient in choline acetylase (CAT). CAT is a marker of acetylcholine biosynthesis enzymes and presynaptic neurons. In addition, cholinergic neurons have also been selectively lost on the septal-diagonal band in Broca’s nucleosystem of AD patients. These neurochemical and histological changes correlate with AD